Biomed Lublin had PLN 4.25 million of net profit, PLN 7.19 million of EBIT profit in 2021

Biomed Lublin recorded PLN 4.25 million in standalone net profit in 2021 compared to PLN 4.44 million profit a year earlier, the company said in the report.

The operating profit was PLN 7.19 million versus PLN 5.93 million profit a year earlier. The EBITDA profit amounted to PLN 13.54 million compared to PLN 11.75 million a year earlier.

Sales revenues amounted to PLN 41.15 million in 2021 compared to PLN 40.16 million a year earlier.

“Biomed Lublin has successfully completed 2021. In the fourth quarter, it generated PLN 14.6 million in revenues, an increase of 21% y / y. The operating profit increased even more - by 39% to PLN 4.3 million. In the entire last year, revenues increased by 2.5% to PLN 41.2 million (close to the record value from 2015), and EBIT by 21% to the record level of PLN 7.2 million. Last year's net profit amounted to PLN 4.25 million and was slightly lower than in 2020 (higher income tax was decisive). What is also noteworthy is the increase in the balance of cash held to PLN 14.3 million at the end of last year (PLN 1.8 million in the previous year) ”- we read in the announcement on the results.

“Over the last few months, we have optimized many processes, as well as outlined further prospects for product development, and prepared a re-launch of several items from our portfolio. At the same time, we increased our production potential, incl. BCG and Distreptazy products, while optimizing costs - hence a much better operating result compared to the previous year ”- commented President Maksymilian Świniarski, quoted in the material.

Biomed-Lublin Wytwórnia Surowic i Szczepionek is a Polish pharmaceutical company operating since 1944. The company produces medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company has been listed on the main market of the WSE since 2015.

Our privacy policy